Stay updated on ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial

Sign up to get notified when there's something new on the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The website has been updated from version v2.14.1 to v2.14.2.
    Difference
    0.3%
    Check dated 2025-02-03T18:33:22.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.3%
    Check dated 2025-01-20T08:54:52.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in this functionality.
    Difference
    1.0%
    Check dated 2025-01-13T05:17:46.000Z thumbnail image
  5. Check
    52 days ago
    Change Detected
    Summary
    The website has been updated from version 2.13.2 to 2.13.3.
    Difference
    0.3%
    Check dated 2024-12-15T11:48:46.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    The website has been updated from version 2.12.2 to 2.13.2, indicating a new release with potential improvements or features.
    Difference
    0.3%
    Check dated 2024-12-07T09:55:00.000Z thumbnail image
  7. Check
    74 days ago
    Change Detected
    Summary
    No new additions were noted, but the website has removed a detailed section regarding data download options and study information fields.
    Difference
    14%
    Check dated 2024-11-22T23:44:00.000Z thumbnail image

Stay in the know with updates to ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page.